The EMBRACE Study The EMBRACE Study

Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will look to see if an energy imbalance in the heart predates the onset of detrimental changes to the pumping function of the heart, if this is detected then we can act earlier to prevent the pumping function deteriorating.

NCT Number	NCT04467411
Lead Sponsor	University of Aberdeen
Conditions	Breast Cancer
Enrollment	70 participants
Start Date	2020-02-01
Primary Completion	2030-08-30 (estimated)
Study Completion	2030-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-30